A Randomized Study of the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Clopidogrel in Three Different CYP2C19 Genotype Groups of Healthy Japanese Subjects-Reference-Cited by-同舟云学术

A Randomized Study of the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Clopidogrel in Three Different CYP2C19 Genotype Groups of Healthy Japanese Subjects

Published:2015 Issue:11 Volume:22 Page:1186-1196
ISSN:1340-3478
Container-title:Journal of Atherosclerosis and Thrombosis
language:en
Short-container-title:JAT

Author:

Kobayashi Masahiko¹,Kajiwara Miyuki²,Hasegawa Setsuo³⁴

Affiliation:

1. Therapeutic Strategy Unit Asia Pacific R&D, Sanofi K.K.

2. Clinical & Exploratory Pharmacology R&D, Sanofi K.K.

3. Sekino Clinical Pharmacology Clinic

4. Pharmaspur Inc.

Publisher

Japan Atherosclerosis Society

Subject

Biochemistry, medical,Cardiology and Cardiovascular Medicine,Internal Medicine

Link

https://www.jstage.jst.go.jp/article/jat/22/11/22_28639/_pdf

Reference19 articles.

1. 1) Bode C, Huber K: Antiplatelet therapy in percutaneous coronary intervention. Eur Heart J Suppl, 2008; 10: A13-A20

2. 2) Montalescot G, Sideris G, Meuleman C, Bal-dit-Sollier C, Lellouche N, Steg PG, Slama M, Milleron O, Collet JP, Henry P, Beygui F, Drouet L; ALBION Trial Investigators: A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes: the ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis) trial. J Am Coll Cardiol, 2006; 48: 931-938

3. 3) Jung JH, Min PK, Lee SH, Sung CW, Choi S, Cho JR, Lee N, Byun KH: Clopidogrel pretreatment before primary percutaneous coronary stenting in patients with acute ST-segment elevation myocardial infarction: comparison of high loading dose (600 mg) versus low loading dose (300 mg). Coron Artery Dis, 2009; 20: 150-154

4. 4) Mehta SR, Tanguay JF, Eikelboom JW, Jolly SS, Joyner CD, Granger CB, Faxon DP, Rupprecht HJ, Budaj A, Avezum A, Widimsky P, Steg PG, Bassand JP, Montalescot G, Macaya C, Di Pasquale G, Niemela K, Ajani AE, White HD, Chrolavicius S, Gao P, Fox KA, Yusuf S; CURRENTOASIS 7 trial investigators: Double-dose versus standarddose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. Lancet, 2010; 376: 1233-1243

5. 5) Isshiki T, Kimura T, Ueno T, Nakamura M, Igarashi K, Yokoi H, Kobayashi M, Ikari Y: Clopidogrel trial in patients with elective percutaneous coronary intervention for stable angina and old myocardial infarction (CLEAN). Int Heart J, 2012; 53: 91-101

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy of Treatment with and without Initial Clopidogrel Loading in Branch Atheromatous Disease;Internal Medicine;2023-10-15

2. Comparison of Prasugrel and Clopidogrel in Thrombotic Stroke Patients with Risk Factors for Ischemic Stroke Recurrence: An Integrated Analysis of PRASTRO-I, PRASTRO-II, and PRASTRO-III;Cerebrovascular Diseases;2023

3. Physiologically Based Pharmacokinetic (PBPK) Modeling of Clopidogrel and Its Four Relevant Metabolites for CYP2B6, CYP2C8, CYP2C19, and CYP3A4 Drug–Drug–Gene Interaction Predictions;Pharmaceutics;2022-04-22

4. A physiologically based pharmacokinetic model of clopidogrel in populations of European and Japanese ancestry: An evaluation of CYP2C19 activity;Pharmacology Research & Perspectives;2022-03-20

5. Effects of Genetic Polymorphisms of Cathepsin A on Metabolism of Tenofovir Alafenamide;Genes;2021-12-20